
AbCellera Reports Q3 2026 Business Results investors.abcellera.com/news…
✓AbCellera is clinical-stage biotech company focused developing antibody-based medicines in the areas of endocrinology, women’s health, immunology and oncology

AbCellera Reports Q3 2026 Business Results investors.abcellera.com/news…

AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026 investors.abcellera.com/news…

AbCellera to Present at Upcoming Investor Conferences in November 2026 investors.abcellera.com/news…

Visit our poster at The Menopause Society 2026 Annual Meeting. We will be presenting Phase 1/2 results on ABCL635, an investigational, potential best-in-class antibody drug for the non-hormonal treatment of vasomotor symptoms. Read more about ABCL635 here: abcellera.com/pipeline/abcl6…

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting investors.abcellera.com/news…

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 investors.abcellera.com/news…

Attend our talk at IMS 2026 to see top-line Phase 2 results on ABCL635, an investigational, potential best-in-class antibody drug for the non-hormonal treatment of vasomotor symptoms. Read more about ABCL635 here: abcellera.com/pipeline/abcl6… #IMSRio2026 #IMS2026

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 investors.abcellera.com/news…

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026 investors.abcellera.com/news…

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants investors.abcellera.com/news…

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants investors.abcellera.com/news…

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile investors.abcellera.com/news…

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 investors.abcellera.com/news…

AbCellera Reports Q2 2026 Business Results investors.abcellera.com/news…

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions investors.abcellera.com/news…

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 investors.abcellera.com/news…